Impact of Gba2 on neuronopathic Gaucher’s disease and α-synuclein accumulation in medaka (Oryzias latipes)
Open Access
- 10 May 2021
- journal article
- research article
- Published by Springer Nature in Molecular Brain
- Vol. 14 (1) , 1-15
Abstract
Homozygous mutations in the lysosomal glucocerebrosidase gene, GBA1, cause Gaucher’s disease (GD), while heterozygous mutations in GBA1 are a strong risk factor for Parkinson’s disease (PD), whose pathological hallmark is intraneuronal α-synuclein (asyn) aggregates. We previously reported that gba1 knockout (KO) medaka exhibited glucosylceramide accumulation and neuronopathic GD phenotypes, including short lifespan, the dopaminergic and noradrenergic neuronal cell loss, microglial activation, and swimming abnormality, with asyn accumulation in the brains. A recent study reported that deletion of GBA2, non-lysosomal glucocerebrosidase, in a non-neuronopathic GD mouse model rescued its phenotypes. In the present study, we generated gba2 KO medaka and examined the effect of Gba2 deletion on the phenotypes of gba1 KO medaka. The Gba2 deletion in gba1 KO medaka resulted in the exacerbation of glucosylceramide accumulation and no improvement in neuronopathic GD pathological changes, asyn accumulation, or swimming abnormalities. Meanwhile, though gba2 KO medaka did not show any apparent phenotypes, biochemical analysis revealed asyn accumulation in the brains. gba2 KO medaka showed a trend towards an increase in sphingolipids in the brains, which is one of the possible causes of asyn accumulation. In conclusion, this study demonstrated that the deletion of Gba2 does not rescue the pathological changes or behavioral abnormalities of gba1 KO medaka, and GBA2 represents a novel factor affecting asyn accumulation in the brains.Keywords
All Related Versions
Funding Information
- Japan Science and Technology Agency (JP16gm0710011)
- Japan Society for the Promotion of Science (15H02540, 18H04041, 15K19486)
- The Ministry of Education,Culture,Sports,Science and Technology (JP23111002)
This publication has 59 references indexed in Scilit:
- A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy BodiesJAMA Neurology, 2013
- Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathiesProceedings of the National Academy of Sciences, 2013
- Improved Immunodetection of Endogenous α-SynucleinPLOS ONE, 2011
- Gaucher Disease Glucocerebrosidase and α-Synuclein Form a Bidirectional Pathogenic Loop in SynucleinopathiesCell, 2011
- Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disordersActa Neuropathologica, 2010
- The risk of Parkinson's disease in type 1 Gaucher diseaseJournal of Inherited Metabolic Disease, 2010
- Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's DiseaseNew England Journal of Medicine, 2009
- Association of Glucocerebrosidase Mutations With Dementia With Lewy BodiesArchives of Neurology, 2009
- Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's diseaseBrain, 2009
- Mutation of β-glucosidase 2 causes glycolipid storage disease and impaired male fertilityJournal of Clinical Investigation, 2006